Newly activated UI Cancer Center clinical trials

Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on ClinicalTrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

A041702: A randomized Phase III Study of Ibrutinib Plus Ibrutinib Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Treating Older Patients (70 years of age or older) With Chronic Lymphocytic Leukemia (CLL)

This Phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax works in treating older adult patients with untreated chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in the body’s immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and obinutuzumab with venetoclax may work better at treating chronic lymphocytic leukemia compared to ibrutinib and obinutuzumab.

Sponsor: Alliance
Principle Investigator: John Quigley, MD

BTCRC-LUN17-139: A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

This is a multi-center Phase II clinical trial of front-line treatment for Stage IV lung cancer patients. All eligible patients will receive: Carboplatin (AUC 5) I.V. day one plus pemetrexed (500mg/m2) I.V. day one plus atezolizumab 1200 mg I.V. day one plus bevacizumab 15 mg/kg I.V. day one every three weeks for up to four cycles. Patients with non-PD after four cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every three weeks until the time of disease progression or intolerable toxicities.

Sponsor: Big Ten Cancer Research Consortium
Principle Investigator: Lawrence Feldman, MD

NRG-BN003: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

This randomized Phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningloma that has been completely removed by surgery. Radiation therapy uses high energy X-rays to kill tumor cells and shrink tumors.

Sponsor: NRG Oncology
Principle Investigator: Martin Kelly Nicholas, MD

Leave a reply

Your email address will not be published. Required fields are marked *